Sensitivity analysis for 30-year NMB associated with routine genetic testing. Base case NMB = 2,702 AUD based on WTP threshold of 64,000 AUD. MODY 1, HNF4A-MODY; MODY 2, GCK-MODY; MODY 3, HNF1A-MODY; MODY 12, ABCC8-MODY; MODY 13, KCNJ11-MODY; Std Care, standard care; SU, sulfonylurea. Ranges for bars: MODY prevalence, 1.0–6.5%; MODY 2 detected by standard care or MPS, 20–83%, and discount rate, 0–5%; MODY 1, 3, 12, and 13 detected using MPS or standard care, 4–53%; probability of SU success, 50–100%; baseline utility for insulin-treated subjects, 0.69–0.86; baseline utilities for non–insulin-treated subjects, 0.86–1.0; HbA1c for insulin-treated subjects, 7.3–8.9% (56–74 mmol/mol); HbA1c for non–insulin-treated subjects, 5.5–7.0% (37–53 mmol/mol); discount rate, 0–5%; and cost of MPS, 80–1,000 AUD. (A high-quality color representation of this figure is available in the online issue.)